CA3201498A1 - Compositions comprising flumazenil and naltrexone and methods for use thereof - Google Patents
Compositions comprising flumazenil and naltrexone and methods for use thereofInfo
- Publication number
- CA3201498A1 CA3201498A1 CA3201498A CA3201498A CA3201498A1 CA 3201498 A1 CA3201498 A1 CA 3201498A1 CA 3201498 A CA3201498 A CA 3201498A CA 3201498 A CA3201498 A CA 3201498A CA 3201498 A1 CA3201498 A1 CA 3201498A1
- Authority
- CA
- Canada
- Prior art keywords
- naltrexone
- flumazenil
- administered
- micrograms
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2020904390 | 2020-11-27 | ||
| AU2020904390A AU2020904390A0 (en) | 2020-11-27 | Compositions and methods | |
| PCT/AU2021/051413 WO2022109677A1 (en) | 2020-11-27 | 2021-11-26 | Compositions comprising flumazenil and naltrexone and methods for use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3201498A1 true CA3201498A1 (en) | 2022-06-02 |
Family
ID=81753640
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3201498A Pending CA3201498A1 (en) | 2020-11-27 | 2021-11-26 | Compositions comprising flumazenil and naltrexone and methods for use thereof |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12521401B2 (https=) |
| EP (1) | EP4251168A4 (https=) |
| JP (1) | JP2024501919A (https=) |
| KR (1) | KR20230110793A9 (https=) |
| CN (2) | CN116648246A (https=) |
| AU (2) | AU2021388076B2 (https=) |
| CA (1) | CA3201498A1 (https=) |
| IL (1) | IL303117A (https=) |
| WO (1) | WO2022109677A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025106574A1 (en) * | 2023-11-14 | 2025-05-22 | Aardwolf Therapeutics, Inc. | Flumazenil for treating post-traumatic stress disorder and anxiety |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008538748A (ja) | 2005-04-07 | 2008-11-06 | ハイシアム， インコーポレイテッド | 不安、物質乱用及び依存の予防のための改良型方法及び組成物 |
| JP2009517393A (ja) * | 2005-11-28 | 2009-04-30 | オレキシジェン・セラピューティクス・インコーポレーテッド | 不安症の治療方法 |
| ES2289935B1 (es) | 2006-07-14 | 2008-12-16 | Juan Jose Legarda Ibañez | Empleo de flumazenilo en la elaboracion de un medicamento para el tratamiento de la patologia depresiva. |
| US9283212B2 (en) * | 2009-02-20 | 2016-03-15 | Palmaya Pty Ltd | Pharmaceutical preparation and delivery system |
| US20150111916A9 (en) * | 2010-04-29 | 2015-04-23 | Annette Channa Toledano | Treatment of pain using a composition of opioid/Toll-like receptor 4 antagonists and dextro enantiomers thereof |
| WO2014120936A2 (en) * | 2013-01-30 | 2014-08-07 | Pharmorx Therapeutics, Inc. | Treatments for depression and other diseases with a low dose agent |
| WO2014186824A1 (en) * | 2013-05-20 | 2014-11-27 | Palmaya Pty Ltd | Treatment of neurological and other disorders |
| WO2015054730A1 (en) * | 2013-10-14 | 2015-04-23 | Palmaya Pty Ltd | Compositions and methods of administering same |
| WO2020181340A1 (en) * | 2019-03-14 | 2020-09-17 | Palmaya Pty Ltd | Treatment of inflammatory diseases of the central nervous system |
-
2021
- 2021-11-26 EP EP21895955.9A patent/EP4251168A4/en active Pending
- 2021-11-26 JP JP2023532700A patent/JP2024501919A/ja active Pending
- 2021-11-26 AU AU2021388076A patent/AU2021388076B2/en active Active
- 2021-11-26 CN CN202180078969.9A patent/CN116648246A/zh active Pending
- 2021-11-26 IL IL303117A patent/IL303117A/en unknown
- 2021-11-26 US US18/039,150 patent/US12521401B2/en active Active
- 2021-11-26 CA CA3201498A patent/CA3201498A1/en active Pending
- 2021-11-26 WO PCT/AU2021/051413 patent/WO2022109677A1/en not_active Ceased
- 2021-11-26 KR KR1020237021602A patent/KR20230110793A9/ko active Pending
- 2021-11-26 CN CN202610170303.0A patent/CN121695144A/zh active Pending
-
2025
- 2025-11-13 AU AU2025267401A patent/AU2025267401A1/en active Pending
- 2025-12-16 US US19/422,283 patent/US20260102405A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021388076A9 (en) | 2024-08-08 |
| CN121695144A (zh) | 2026-03-20 |
| AU2021388076B2 (en) | 2025-08-14 |
| US20240000796A1 (en) | 2024-01-04 |
| WO2022109677A1 (en) | 2022-06-02 |
| EP4251168A1 (en) | 2023-10-04 |
| CN116648246A (zh) | 2023-08-25 |
| JP2024501919A (ja) | 2024-01-17 |
| IL303117A (en) | 2023-07-01 |
| EP4251168A4 (en) | 2024-11-06 |
| AU2025267401A1 (en) | 2025-12-04 |
| KR20230110793A (ko) | 2023-07-25 |
| US20260102405A1 (en) | 2026-04-16 |
| KR20230110793A9 (ko) | 2024-11-13 |
| US12521401B2 (en) | 2026-01-13 |
| AU2021388076A1 (en) | 2023-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2746000C2 (ru) | Состав для ингибирования образования агонистов 5-ht2b и способы его применения | |
| US20250025453A1 (en) | Methods of using factor b inhibitors | |
| CN102133171A (zh) | 延缓释放阿立哌唑的可注射组合物 | |
| US20260102405A1 (en) | Compositions comprising flumazenil and naltrexone and methods for use thereof | |
| EP1896025B1 (en) | Scopolamine for the treatment of depression and anxiety | |
| CN108348527A (zh) | 用于治疗癫痫的方法 | |
| RU2268725C2 (ru) | Комбинация лекарственных препаратов, включающая миртазапин, для лечения депрессии и связанных расстройств | |
| EP2670405B1 (en) | Combinations comprising macitentan for the treatment of glioblastoma multiforme | |
| US9700565B2 (en) | Method of treating mixed lineage leukemia gene-rearranged acute lymphoblastic leukemias | |
| US20110195898A1 (en) | Treatment of alzheimer's disease and mild cognitive impairment using gnrh-i analogs and one or more of acetylcholinesterase inhibitors and nmda receptor antagonists | |
| US20170065579A1 (en) | Sustained Release Low Dose Formulations and Uses Thereof | |
| US20050255096A1 (en) | Combination treatment for acute myocardial infarction | |
| JP2005530751A (ja) | 末端成長ホルモン（ｇｈ）断片を使用する鬱病の制御方法 | |
| JP2026506073A (ja) | エフロルニチンを使用する組成物および方法 | |
| JP6702883B2 (ja) | 向神経活性ペプチドの安定な組成物 | |
| US20110301102A1 (en) | Compositions and methods for treating myelodysplastic syndrome | |
| EP4364742A1 (en) | Pharmaceutical composition for treating solid tumors | |
| EP0254313B1 (en) | Use of ketamine for the manufacturing of medicaments for prevention or reduction of the effects of stroke in a subject having increased risk for stroke | |
| Lucas et al. | Shaking, chills, and rigors with once‐daily gentamicin | |
| AU2006246490B8 (en) | Use of flumazenil in developing a drug for the treatment of alcohol dependence | |
| CN118829427A (zh) | 治疗腹型肥胖、高甘油三酯血症和/或血糖受损受试者的方法 | |
| CN116456998A (zh) | 咖啡因组合物 | |
| WO2005097138A2 (en) | Combinations comprising oxcarbazepine to treat affective disorders | |
| CHECK | 1.07Approach to Bipolar Diathesis in Schizophrenia Spectrum Patients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241118 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241118 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241118 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251117 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251117 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20251126 |
|
| D16 | Fast track examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D16-D108 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ADVANCED EXAMINATION REQUESTED - PPH Effective date: 20251126 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20251126 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251126 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20251229 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20251229 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251229 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251229 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251229 |
|
| D17 | Fast track examination accepted |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D17-D112 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ADVANCED EXAMINATION DETERMINED COMPLIANT - PPH Effective date: 20251230 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251230 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260105 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260108 |